PharmAla Biotech Unit Signs MDMA Distribution Agreement With Rua Bioscience in New Zealand
MT newswire2026/10/08 20:5604:56 PM EDT, 10/08/2026 (MT Newswires) -- PharmAla Biotech Holdings (MDMA.CN) after the market close on Thursday said its PharmAla Biotech unit signed a distribution and license agreement with Rua Bioscience under which Rua will import, distribute and sell PharmAla's LaNeo MDMA in New Zealand. The agreement follows New Zealand regulator Medsafe's Sept. 4 approval allowing two psychiatrists to prescribe pharmaceutical-grade MDMA for post-traumatic stress disorder. Rua will supply PharmAla's 40-milligram LaNeo MDMA capsules to authorized prescribers in New Zealand. The first shipment will be provided on a consignment basis. PharmAla supplies clinical trials and authorized prescribers internationally, including in Australia, where authorized psychiatrists have prescribed MDMA since 2023.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canadian used car dealer UC Automotive (UCAU.RC.US) files for IPO in the US: aims to raise 29 million USD and list on Nasdaq
Canadian used car dealer UC Automotive has applied for a Nasdaq IPO, aiming to raise up to $29 million, with its main focus on the Greater Vancouver market. Kingswood is the sole underwriter.
Swiss Franc weakens as Fed hawkish outlook lifts USD/CHF
Crypto prices
More
